Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database
2014
Abstrakt
Data of 235 unselected MCL patients from the Czech Lymphoma Group Database were analysed. MIPI divided all patients into subgroups of low-risk (22%), intermediate-risk (29%) and high-risk (49%) with median overall survival:105.8 vs. 54.1 vs. 24.6 months (p < 0.001).
We confirmed Ki-67 index to be a powerful single prognostic factor for overall survival (64.4 vs. 20.1 months, p < 0.001) for all patients. Our results confirmed clinical relevance of MIPI and Ki-67 for risk stratification in MCL also in the rituximab era.